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Abstract 
Background: Malaria causes a significant burden in highly endemic areas where children and pregnant women are 
more susceptible to severe disease and death, however, in low transmission settings malaria in pregnant women is 
less frequent. The aim of this study was to provide information of clinical profile, anti‑parasite host immune responses 
and parasite genotyping of pregnant women with malaria in low endemic areas of Colombia.
Methods: This was a descriptive study conducted through passive surveillance in 1328 individuals from three 
endemic areas of Córdoba, Nariño and Chocó departments between 2011 and 2013. Trained physicians confirmed 
the pregnancy status and recorded clinical and epidemiological information. Haematological parameters, as well as 
hepatic and renal function, anti‑malarial antibodies and parasite genotypes were evaluated.
Results: A total of 582 women presented with malaria infection, 34 of whom were pregnant (5.8 %), and most were 
infected by Plasmodium falciparum (n = 24). In 44 % (n = 15) of the women, the infection occurred during the first 
half of pregnancy. Although uncomplicated disease and parasitaemia ≤20,000 parasites/µL were common (n = 31), 
three women (8.8 %) infected by P. falciparum were classified as severe cases. Mild to moderate anaemia (68 %) and 
mild thrombocytopaenia (41 %) were the most frequent blood alterations and in four women acute renal failure 
was observed. Six women presented a second malaria episode during pregnancy mainly caused by P. vivax (n = 5), 
although no direct evidence of relapse was found by genotyping. Two out of the six women presenting a second 
malaria episode had severe malaria. A low prevalence of specific anti‑parasite antibodies was found. Microsatellites 
indicated that all P. vivax infections involved multiple lineages whereas all but one P. falciparum infections harboured 
single genotypes.
Conclusions: Most malaria infected pregnant women displayed uncomplicated malaria, although a few of them 
with a second malaria episode presented an increased risk of severe malaria which appeared to be associated with 
malaria transmission intensity and not with levels of anti‑parasite antibodies. The effects of severe malaria in both 
mother and fetus warrant future studies in low transmission settings.
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Background
Malaria in pregnancy (MiP) is one of the leading causes 
of maternal and child morbidity and mortality worldwide, 
mainly in high endemic areas [1–3]. About 125 million 
women are at risk of acquiring malaria infections dur-
ing pregnancy [2], mainly in Africa where Plasmodium 
falciparum is the predominant malaria parasite. Outside 
Africa, Plasmodium vivax infections are predominant and 
every year about 90 million pregnant women are exposed 
to the risk of infection mostly in the Asia–Pacific region 
only [2, 3] and about three million in Latin America [2].
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Malaria infection during pregnancy is associated with 
a broad spectrum of clinical manifestations ranging from 
acute uncomplicated to severe cases and death of both 
mothers and neonates [1, 4–6]. A higher risk of severe 
anaemia has been reported in P. vivax infected multi-
gravidae [7–9]. Furthermore, P. vivax in Latin America 
has been associated with severe malaria [10–12], mod-
erate-to-severe anaemia and low birth weight [8]. From 
~390,000 malaria clinical cases reported in Latin Amer-
ica [13], low frequency of MiP cases (10  %) [8, 10–12, 
14] with moderate-to-high severe cases (4–9  %) and 
low mortality (0–0.2  %) [8, 11, 12] have been observed. 
A comparable prevalence of malaria-associated deaths 
has been reported in the Thai-Myanmar border where 
the frequencies of annual fatal cases in pregnant women 
for P. falciparum and P. vivax were estimated as 0.28  % 
(12/4158) and 0.023 % (1/4298), respectively [6].
Given its public health importance, understanding 
the clinical manifestations of malaria during pregnancy 
has been the focus of several investigations. In particu-
lar, there is evidence indicating that the clinical presen-
tation of the disease in pregnant women is modified by 
the immune status of the patient [5] as well as by the 
presence of multiple parasite genotypes [15, 16]. How-
ever, such associations may vary across the disease’s 
broad geographic distribution. Although studies in Afri-
can pregnant women infected with P. falciparum found 
that levels of specific antibodies rapidly decrease during 
pregnancy rendering women more susceptible to MiP 
complications [17]; studies in Thailand, where both P. 
falciparum and P. vivax co-exist, have not shown such a 
clear pattern. One such study found a high variability of 
antibodies over time and its maintenance was associated 
with the number of malaria infections [18]. Regarding the 
proposed association between presence of multiple para-
site genotypes for P. vivax and P. falciparum infections 
and pregnant women, the issue remains unsolved due to 
the paucity of studies that include parasite genetics [15, 
16, 19, 20].
This study was performed in Colombia, a South 
American country with a low average malaria trans-
mission. Colombia is the third contributor of malaria 
cases in Latin America, after Brazil and Venezuela [13] 
with approximately 10 million people currently living in 
areas with risk of malaria transmission. It is estimated 
that at least one million women of reproductive age 
(15–49 years) live in three of the most malaria endemic 
areas (Córdoba, Nariño and Chocó) of the country [21]. 
The aim of this study was to provide information from 
endemic areas in Latin America where, unlike other 
regions with low malaria transmission intensity [3, 6, 7, 
9], there are few studies on MiP [10–12, 14]. Further-
more, Latin America MiP studies have not reported 
levels of humoral immune responses and only one study 
included parasite genotyping [19], thus the frequency 
of relapses in pregnant women or the role played by the 
presence of multiple parasite genotypes, if any, are not 
usually addressed. In this study, the clinical profile of a 
group of pregnant women acutely infected with P. falci-
parum and P. vivax is reported.
Methods
Study design, sites and ethical issues
This is a descriptive study in Colombian pregnant women 
carried out using data collected between 2011 and 2013 
as part of a passive surveillance study conducted in Tier-
ralta (Córdoba department), Quibdó (Chocó depart-
ment) and Tumaco (Nariño department) Colombia, 
to characterize the malaria clinical profile [22]. These 
endemic regions have distinct malaria transmission 
intensities and parasite distribution where P. vivax was 
more frequent in Tierralta (~85  %), whereas P. falcipa-
rum was more frequent in Tumaco (~79 %) and Quibdó 
(~70 %) [23]. The average annual parasite incidence (API) 
between 2011 and 2013 in those sites was 6.7, 10.3 and 
25, respectively.
Of a total of 1328 patients with symptomatic malaria 
enrolled in these three sites, 34 were pregnant women. 
The study protocol was previously approved by the Insti-
tutional Review Board (IRB) affiliated to the Malaria 
Vaccine and Drug Development Center (MVDC, Cali). 
Declaration of free willingness to participate in the study 
and written informed consent (IC) or an informed assent 
(IA) in the case of women <18 years of age were obtained 
from each participant. After blood samples were drawn, 
the local health provider treated all malaria infected 
women using the Colombian protocol [24]. Women 
infected with P. falciparum received artemether plus 
lumefantrine (orally, twice a day over 3  days), whereas 
those infected with P. vivax were treated only with 
chloroquine (orally, 25  mg/kg provided in three doses). 
Severe malaria cases were treated at the hospital with 
intravenous artesunate (2.4  mg/kg time 0, with repeat 
doses at 12 and 24 h), followed by oral artesunate (once a 
day to complete 7 days). All women were asked to return 
7 days after treatment for thick blood smear (TBS) con-
trol and at any moment if malaria symptoms were pre-
sented. Intermittent preventive treatment (IPTp) was not 
provided, because it is not included in the Colombian 
national policy.
Case definition
Patients were classified as suffering from uncom-
plicated or severe MiP according to the clinical and 
laboratory criteria defined by the WHO [25] and the 
Colombian MoH guidelines [24]. The latter are more 
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conservative in some definitions based on previous 
evidence i.e. severe anaemia (Hb  <7  g/dL), renal dys-
function (serum creatinine >1.5 mg/dL), severe thrombo-
cytopaenia (≤20,000 platelets/µL) and hyperparasitaemia 
(>50,000 parasites/μL). Uncomplicated MiP was defined 
as a clinical malaria case with the presence of Plasmo-
dium spp. in the peripheral blood without severity crite-
ria. Severe MiP was defined as one or more of the clinical 
or laboratory parameters previously described by either 
the Colombian or WHO guidelines [24, 25], regardless 
of the malaria parasite species. Trained physicians of the 
study staff completed a standard clinical evaluation and 
physical examination in all women and then blood sam-
ples were obtained. In all women, the pregnancy was 
confirmed using pregnancy dipstick test (Abon Biop-
harm Company, China). The gestational age was meas-
ured calculating the days since the beginning of the last 
menstrual period.
Laboratory tests
Whole blood (15  mL) was collected by venipuncture at 
the time of enrolment before the anti-malarial treat-
ment was provided. Malaria diagnosis was performed 
by microscopic examination of Giemsa-stained TBS, 
which were independently examined by two experienced 
malaria microscopists. Parasite density (parasites/µL) 
was estimated by counting the number of parasites per 
200 leukocytes and normalized using the actual leuko-
cyte counts of each woman [(number of parasites × leu-
kocyte counts)/200 leukocytes]. Malaria parasite species 
was retrospectively confirmed in all samples by real time 
PCR, as described elsewhere [22]. Automated complete 
blood cell counts (KX-21 N, Sysmex, Japan) and urine 
analysis (dipstick and microscopic) were performed at 
each point-of-care (POC). Blood chemistry profiles in 
frozen sera were analysed using commercial kits in a ref-
erence laboratory in Cali (Asoclinic Ltda) following man-
ufacturer’s instructions. Renal (creatinine and blood urea 
nitrogen, BUN) and hepatic function (total bilirubin and 
aminotransferases, ALT and AST) parameters were ana-
lysed spectrophotometrically (BTS-350 Chemistry Ana-
lyser, Biosystems SA, Spain) using commercially available 
kits (Biosystems SA, Spain).
ELISA and IFA tests for specific malaria antibodies
Specific IgG anti-malarial antibodies in serum were 
determined both by immunofluorescent antibody (IFA) 
and enzyme-linked immunosorbent assay (ELISA) tests. 
Because both P. vivax and P. falciparum are present in the 
study areas, sera from all patients were analysed for anti-
bodies to both parasite species. IFA tests were performed 
using P. vivax and P. falciparum blood stages antigen 
preparations derived from infected patients or from 
in vitro cultures respectively as previously described [26]. 
Antibody titers were estimated using twofold serial dilu-
tions of the test sera starting at 1:20. ELISA test was used 
to determine the presence of total IgG specific to the P. 
vivax circumsporozoite protein (PvCS, N-terminal frag-
ment), the merozoite surface protein-1 (PvMSP-1, r200L 
recombinant protein) as well as the response against P. 
falciparum CS (PfCS, N-terminal) and MSP-1 (PfMSP-1, 
19 kDa recombinant protein) as described elsewhere [27]. 
Optical Density (OD) at 405  nm was measured using a 
BioTek ELISA Reader (BioTek, Winooski, VT). Cut-off 
values were calculated as three SD above the mean OD 
value of negative control sera. A sample was considered 
positive when the OD at 1:200 dilution was higher than 
the cut-off value. Results were expressed as a reactivity 
index (RI), defined as OD values of test sample divided by 
the cut-off value.
DNA extraction and microsatellite (STRs) genotyping
Whole blood samples collected with EDTA anticoagu-
lant were used for extraction and purification of genomic 
DNA using the QIAamp DNA Blood kit according to 
manufacturer’s instructions (Qiagen Inc, CA, USA). The 
DNA was eluted and stored at −20  °C until use. Geno-
typing was performed using fluorescently labeled PCR 
primers. Those with low parasitaemia were amplified by 
whole genome amplification using the REPLI-g Mini Kit 
(Qiagen Inc, CA, USA). A set of 10 standardized STRs 
loci for P. vivax and nine for P. falciparum selected from 
an extensive pool of choices that have been explored [28] 
were used. In the case of P. vivax, the following loci were 
included in the analyses: MS2, MS5, MS6, MS15 [29] and 
14.185, 7.67, 8.332, 2.21, 10.29, 8.332 [30]. Loci POLYa, 
TAA60, ARA2, Pfg377, TAA109, TAA81, TAA42-3, 
TA40 and PfPK2 were amplified for P. falciparum [31]. 
Fluorescently labelled PCR products were separated 
on an Applied Biosystems 3730 capillary sequencer and 
scored using Gene Marker v1.95 (SoftGenetics LLC). The 
presence of one or more additional alleles at a particular 
locus was interpreted as a co-infection with two or more 
genetically distinct clones in the same isolate [28].
Statistical analysis
Study data were collected and managed using REDCap 
(Nashville, Tennessee, USA) electronic data capture tool 
[32]. Data were analysed with the statistical software 
MATLAB® 2013a (The MathWorks, Inc., Natick, Mas-
sachusetts, USA). The nominal variables were analysed 
using descriptive statistics. The Mann–Whitney U test 
was used to compare two groups and Wilcoxon signed 
rank test for paired data. Spearman’s rank correlation (rs) 
was used to assess the correlation between numeric vari-
ables. Fisher’s exact test was used to compare proportion 
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differences. A p value <0.05 was considered statistically 
significant.
Results
Epidemiological characteristics of the pregnant women
From 1328 subjects infected with malaria, 582 were 
women and 34 of them were pregnant (5.8  %). Most 
patients were ≤25 years of age (76 %; range 14–41 years) 
and a high proportion of them (n  =  15; 44  %) became 
infected in the first half of pregnancy, seven of them dur-
ing the first trimester. Afro-descendants (n =  19; 56  %) 
and mestizos (n = 13; 38 %) were the most frequent eth-
nic groups and the remainder corresponded to indig-
enous population. In total, 62 % (n = 21) of women had 
resided in the malaria-endemic region (>2 years, median 
4.5 years) and 88 % (n = 30) were working at home. Half 
of the women self-reported previous lifetime malaria epi-
sodes and in eight women this happened in the previous 
year (Table 1).
Malaria diagnosis and clinical manifestations
All malaria infections were confirmed by real time PCR 
as P. falciparum or P. vivax monoinfection, with P. fal-
ciparum as the most prevalent (n =  24; 71  %, Table  1). 
Most cases (91.2  %) presented with low to moderate 
parasitaemia, ≤20,000 parasites/µL. The median P. vivax 
parasitaemia (7547  parasites/µL; IQR 4, 499–10,721; 
min–max 1740–15,100) appeared higher than in P. fal-
ciparum infections (2509 parasites/µL; IQR 869–10,083; 
min–max 355–36,919). Such difference was not statisti-
cally significant.
Seven women (21 %) attended at the POC for diagnosis 
within 48 h after symptoms onset (range 0–22 days) and 
only four women reported >15 days of illness (Table 1). 
At day 7 all women had negative TBS results. Accord-
ing to the clinical and laboratory parameters, uncompli-
cated malaria was the most frequent clinical syndrome 
(91.2 %). However, after evaluation at the POC 19 of the 
34 patients were referred to a hospital for observation 
and treatment. The classical triad of fever, chills and 
sweating together with headache was reported by 24/34 
women (71 %). Myalgia/arthralgia (74 %), asthenia (50 %), 
nausea (50 %), anorexia (47 %) and abdominal pain (44 %) 
were frequently reported independently of the malaria 
parasite species (Fig.  1). On physical examination, pal-
lor (41 %), fever (32 %) and abdominal pain on palpation 
(21 %) were observed. Notably, seven women (four with 
P. falciparum and three with P. vivax) reported one or 
more of the following symptoms associated with preg-
nancy: reduction of foetal movement, preeclampsia signs 
or abdominal and pelvic pain (sudden and intense) with-
out signs of preterm delivery.
Haematological alterations
There were no significant differences for haemato-
logical parameters induced by the two parasite species 
(Table  2). Mild-to-moderate malaria-related anaemia 
was observed in 68  % of the studied women, with only 
one who suffered a second malaria episode during the 
current pregnancy, presenting severe anaemia (Hb <7 g/
dL). Six women (18  %) presented microcytic anaemia. 
Haemoglobin levels remained significantly associated 
with age regardless of the parasite species (rs  =  0.358; 
p =  0.038). Thrombocytopaenia (<150,000  platelets/µL) 
was found in 41 % (n = 14) of the women, but only three 
of them had  <100,000  platelets/µL. A negative correla-
tion was found between platelets counts and parasitae-
mia (rs = −0.557; p  <  0.001), but it was not associated 
with parasite species, age or weeks of gestation (data not 
shown). Mild leukopaenia (18  %), lymphopaenia (15  %) 
and neutropaenia (5 %) were observed mainly in P. falci-
parum infected women.
Hepatic and renal alterations
Median values of renal and hepatic function labora-
tory parameters were similar in both parasites spe-
cies (Table 2), although mild (10 %) to moderate (16 %) 
hyperbilirubinaemia (total bilirubin range 1.0–2.1  mg/
Table 1 Characteristics of pregnant women and malaria history
Significant data are highlighted in italics
a  IQR interquartile range
b p value using the Mann–Whitney U test between P. falciparum and P. vivax
Plasmodium falciparum  
(n = 24)
Plasmodium vivax  
(n = 10)
P valueb
Median (IQR)a Median (IQR)
Age (years) 20 (17–28) 19 (17–23) 0.344
Weeks of gestation 24 (20–30) 16 (8–23) 0.033
Time of residence (years) 6 (1.5–15.5) 0.3 (0.1–7.5) 0.026
Number of previous malaria episodes 2 (1–4) 3 (1–4) 0.681
Days of illness 5 (3–8) 4 (3–7) 0.623
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dL) was observed particularly in P. vivax infections. 
Hepatic enzymes (ALT and AST) were altered in 21  % 
(n = 7) of women, all of them infected with P. falcipa-
rum. Proteinuria (61.8  %), ketonuria (29.4  %) and leu-
kocyturia (23.5  %) were observed in women infected 
with either parasite species. Acute renal failure of pre-
renal origin (BUN: creatinine  >20) was found in four 
women, of whom two had also proteinuria and cholu-
ria. Using standard criteria in pregnancy [33], eight 
women (24  %) had alterations in the serum creatinine 
levels (>0.8  mg/dL) and six (18  %) in the BUN levels 
(>12 mg/dL), mostly infected by P. falciparum, 6/8 and 
4/6, respectively.
Second malaria episode during gestation
As described above, patients were asked to return to the 
POC if malaria symptoms recurred. A total of six women 
(one with P. falciparum and five with P. vivax) presented 
with a second malaria episode by the same parasite spe-
cies, even after receiving treatment for asexual para-
site stages in the first episode; however primaquine was 
not administered for P. vivax due to its contraindication 
during pregnancy. Since the follow-up was passive, new 
episodes, complications or self-treatment in some of the 
women cannot be ruled out.
Median time between episodes was 59  days (IQR: 
37–158; range 27–200 days) and patients reported simi-
lar signs, symptoms, and days of illness before consulta-
tion (median 4 days) but lower parasitaemia than in the 
first episode (median 6759 vs 3030 parasites/µL, respec-
tively; Fig.  2), except for the woman infected by P. fal-
ciparum presenting higher parasitaemia in the second 
episode. All six women presenting with a second episode 
were anaemic with a lower Hb than in the first episode 
(Fig. 2). Most patients presented normal values for other 
laboratory parameters (Table 3).
Fig. 1 Frequency of clinical manifestations in P. falciparum and P. 
vivax infections. Percentages of women presenting every clinical 
manifestation are shown. All women reported more than one. Triad 
corresponds to women presenting fever, chills and sweating. No 
significant differences were observed
Table 2 Laboratory parameters in  pregnant women 
with malaria
BUN blood urine nitrogen, ALT alanine aminotransferase, AST aspartate 
aminotransferase
a  IQR interquartile range
b p value using the Mann–Whitney U test between P. falciparum and P. vivax
Laboratory parameters P. falciparum 
(n = 24)
P. vivax  
(n = 10)
p valueb
Median (IQR)a Median (IQR)
Haemoglobin (g/dL) 10.1 (9.1–11.0) 10.6 (9.2–11.5) 0.461
Platelets count (×103/µL) 163 (132–242) 143 (124–197) 0.281
Leukocytes (×103/µL) 5.6 (4.6–6.8) 6.2 (5.9–7.6) 0.073
Neutrophils (×103/µL) 3.8 (2.9–4.7) 3.8 (3.6–4.6) 0.545
Lymphocytes (×103/µL) 1.5 (1.1–2.0) 2.4 (1.4–3.1) 0.054
Total bilirubin (mg/dL) 0.6 (0.2–0.8) 0.6 (0.3–1.3) 0.493
ALT (U/L) 13.0 (10.0–20.0) 13.5 (10.5–17.0) 0.784
AST (U/L) 25.0 (16.0–33.0) 22.5 (17.5–27.5) 0.318
Creatinine (mg/dL) 0.7 (0.7–0.9) 0.7 (0.6–0.8) 0.290
BUN (mg/dL) 8.0 (6.0–11.0) 8.5 (7.0–12.0) 0.317
Fig. 2 Laboratory parameters for the first and second malaria 
episodes. Data of women infected with P. vivax (n = 5; open circles) 
and P. falciparum (n = 1; closed circle) are shown. Statistical differences 
between both episodes were calculated using the Wilcoxon signed 
rank test; all of them were not significant (p > 0.05)
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Severe malaria
Three P. falciparum cases (3 of 34 women = 8.8 %) were 
classified as severe malaria during the first episode: 
two women developed prostration and required hos-
pitalization, and one had severe thrombocytopaenia 
(20,000 platelets/µL) without spontaneous bleeding. The 
three women also presented moderate anaemia (mean 
Hb 8.7 ± 0.1 g/dL). All women received anti-malarial and 
supporting treatment according to severity of infection as 
recommended by Colombian guidelines [24].
In addition, two 15 year-old women presenting with a 
second malaria episode during pregnancy, were severe. 
One woman with.P. falciparum infection (12,932  para-
sites/µL) presented hepatic dysfunction with hyper-
bilirubinaemia (total bilirubin 4.7  mg/dL) and clinical 
jaundice, while another with P. vivax (3655  parasites/
µL), presented severe anaemia (Hb 4.4 g/dL) with general 
pallor without co-incidental infections. No deaths were 
reported.
Antibody responses
A total of 47.1 % (n = 16) and 52.9 % (n = 18) pregnant 
women had antibodies to whole P. vivax and P. falcipa-
rum blood stages by IFA test respectively and significant 
differences were observed between antibody specific 
parasite species (Table 4) with low antibody titers rang-
ing between 1:20 and 1:640 (Fig.  3). When antibodies 
were determined by ELISA the frequency of responders 
for each antigen were low-to moderate: PvCS (32.4  %), 
PvMSP-1, (55.9 %), PfCS (26.5 %) and PfMSP-1 (73.5 %); 
8.8 % (n = 3) and 47 % (n = 16) women were double posi-
tive for P. vivax and P. falciparum CS and MSP-1 anti-
gens, respectively, however antibody levels displayed low 
titers (Fig.  4). Differences in reactivity (RI) between P. 
falciparum and P. vivax infected women were observed 
for PfCS (median 0.90 vs 0.59; p = 0.023) and PfMSP-1 
(median 3.66 vs 1.29; p = 0.008), respectively. In contrast, 
the RI values for PvCS and PvMSP-1 were similar in P. 
falciparum and P. vivax infected women (median 0.91 vs 
0.89 and 1.18 vs 0.80, respectively). In women who had 
two P. vivax episodes during pregnancy an increase in the 
RI for PvMSP-1 during the second episode was observed 
(Fig. 5). Likewise in the woman infected with P. falcipa-
rum the RI for PfMSP-1 increased (0.58 vs 6.81). No asso-
ciation was found between antibody titers and disease 
severity.
Microsatellite (STRs) genotyping
A total of 22/34 parasite samples including P. falciparum 
(14/24) and P. vivax (8/10) were analysed using a set of 
physically unlinked microsatellite loci (Additional file 1). 
Most of the P. falciparum infections were single clonal 
infections (13/14), with six genotypes in 14 samples and 
only one sample with two genotypes differentiated by 
one locus. In comparison, P. vivax was more diverse, with 
all eight samples with two or more genetically distinct 
lineages.
In the woman presenting two P. falciparum episodes, 
the same genotype was found in both episodes, whereas 
the two women who presented two P. vivax episodes had 
distinct genotypes with differences in at least three loci 
between episodes (Additional file 1). In the P. falciparum 
patient the second episode corresponded to a severe case.
Discussion
Despite the study areas being among the most endemic 
regions of Colombia [23], the low MiP prevalence 
observed (34/582; 5.8  %) was expected as malaria prev-
alence has significantly decreased in the country dur-
ing the last decade [34], probably due to significant 
efforts by the National Malaria Control Programme 
Table 3 Parameters in the six pregnant women presenting 
a second malaria episode
BUN blood urine nitrogen, ALT alanine aminotransferase, AST aspartate 
aminotransferase
a  IQR interquartile range
b  p value using the Wilcoxon signed rank test





Median (IQR)a Median (IQR)
Weeks of gestation 18 (10–29) 33 (23–38) 0.031
Days of illness 4 (2–13) 4 (2–6) 0.625





Haemoglobin (g/dL) 10.2 (8.9–11.5) 9.6 (6.3–10.5) 0.079
Platelets count (×103/µL) 155 (133–306) 167 (131–264) 0.844
Leukocytes (×103/µL) 6.2 (5.1–8.6) 7.5 (5.4–9.3) 0.688
Neutrophils (×103/µL) 3.8 (3.7–5.1) 4.7 (3.6–7.1) 0.313
Lymphocytes (×103/µL) 2.4 (1.2–3.4) 2.0 (1.2–2.7) 0.563
Total bilirubin (mg/dL) 0.43 (0.24–1.43) 0.43 (0.20–3.01) 0.374
ALT (U/L) 12.5 (9.5–19.0) 11.5 (6.5–16.0) 0.346
AST (U/L) 23.0 (17.5–27.0) 30.0 (18.5–34.0) 0.231
Creatinine (mg/dL) 0.7 (0.6–0.7) 0.7 (0.5–0.8) 1.000
BUN (mg/dL) 8.5 (6.5–10.0) 8.5 (7.0–11.0) 0.563
Table 4 Seroprevalence against Plasmodium whole blood-
stages as assessed by IFA
Most frequent and significant data are highlighted in italics
a  p value using the Fisher’s exact test between P. falciparum and P. vivax
Asexual stages of P. falciparum (n = 24) P. vivax (n = 10) p valuea
n (%) n (%)
P. falciparum 16 (66.7 %) 0 (NA) 0.001
P. vivax 9 (35.5 %) 9 (90 %) 0.008
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(NMCP) to decrease the malaria incidence in the frame 
of control programmes sponsored by the Global Fund 
for Aids, Tuberculosis and Malaria (GFATM). However, 
although reducing malaria transmission is important, it 
has recently been suggested that the concomitant reduc-
tion in naturally acquired immunity to malaria increases 
the risk of adverse consequences for infected pregnant 
women [17].
Previous studies carried out in Colombia (Córdoba and 
Antioquia) indicated a higher prevalence (9  %–14  %) of 
MiP [12, 35, 36] and similar results were reported from 
Brazil and Bolivia, where prevalence of MiP ranged 
between 4 and 12 %, mainly due to P. vivax [8, 11]. Indeed, 
as reported here severe malaria in pregnant women 
was not rare (3/34; 8.8  %), with figures similar to those 
reported in low transmission areas in Colombia (15/166; 
9 %) [12] and Thailand (9/121; 7.4 %) [1]. Suggesting that 
Fig. 3 Seroprevalence of IgG antibodies against whole blood stages tested by IFA. Frequency of IgG titers against (a) P. falciparum and (b) P. vivax
Fig. 4 Antibody response against Plasmodium antigens during 
patent malaria infection. Response against PvCS, PvMSP‑1, PfCS and 
PfMSP‑1 was determined by ELISA. Values are expressed as reactivity 
index (RI) defined as sample OD at 1:200 serum dilutions divided by 
the cut‑off value. Solid lines show the median RI in each group Fig. 5 Antibody response against P. vivax antigens in women with 
two malaria episodes by P. vivax. Antibody response against (a) PvCS 
and (b) PvMSP‑1 was determined by ELISA. Values are expressed as 
reactivity index (RI) defined as sample OD at 1:200 serum dilutions 
divided by the cut‑off value. Statistical differences between both 
episodes were calculated using the Wilcoxon signed rank test
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malaria diagnosis and anti-malarial treatment are occur-
ring late since only 21  % of studied women consulted 
within the 48 h after symptoms onset, with a median of 
4 days. In a recent study conducted in Colombia, signifi-
cant awareness of the importance of early diagnosis and 
prompt treatment was found, which are becoming more 
common. Late screening in MiP would also explain that 
several women developed alterations such as mild-to-
moderate anaemia (23/34), thrombocytopaenia (14/34) 
and renal dysfunction of pre-renal origin (8/34), which 
could significantly contribute to the risk of complications 
and death of both mother and fetus by increasing the risk 
of preterm delivery, low birth weight and post-partum 
haemorrhages [3, 5]. Despite the absence of fatalities in 
this study, those findings highlight the importance of 
early diagnosis and prompt treatment to decrease the risk 
of complication in low transmission settings.
Importantly, younger maternal age (≤25  years) 
observed in 76  % of patients and early malaria infec-
tion (<20  weeks of gestation) in 44  %, appeared associ-
ated with clinical presentation and may to increase the 
risk of intrauterine growth restriction [37, 38]. A similar 
age in pregnant women with malaria has been previously 
reported in Colombia [12, 19, 36], which may be related 
to the malaria transmission intensity and social and civil 
conflicts in this region (Arévalo-Herrera et  al, unpub-
lished data), indicating an important target population 
for malaria control programmes. In this study, moder-
ate anaemia was associated with all severe malaria cases 
(3/3) and the presence of a second malaria episode (6/6) 
as reported in P. falciparum infections [39]. Although 
P. vivax is more prevalent in Colombia, most MiP cases 
reported here were induced by P. falciparum, particularly 
in Tumaco and Quibdó, two areas where population is 
Afro-descendant with high prevalence of Duffy-negative 
individuals [40].
Previous exposure to malaria infection might have con-
tributed to a higher percentage of uncomplicated cases. 
Between 47 and 53  % of women had antibodies against 
whole blood stages, which confirmed self-reported pre-
vious exposure to parasite. A previous study demon-
strated the development of significant protection from 
clinical symptoms in young adults from the study regions 
exposed to experimental P. vivax infection [41], in addi-
tion, it has been suggested that multiplicity of infections 
may be involved in the gradual acquisition and mainte-
nance of malaria immunity [15]. Most women infected 
with P. falciparum harboured single genotypes regardless 
of disease severity; those also reported longer residence 
in the endemic areas. In contrast, all infections with 
P. vivax involved multiple genotypes. Such differences 
between P. falciparum and P. vivax have been observed 
in many malaria endemic areas [42]. Although the small 
sample size precludes further analysis between multi-
ple genotypes and severity association in MiP, recently 
it was found that having a multiclonal P. vivax infection 
is associated with severe malaria in Colombian patients 
[43]. In this study, women presenting with a second P. 
vivax episode displayed different genotypes suggesting 
a new infection. However, a relapse cannot be ruled out 
due to the restriction of using primaquine during preg-
nancy [44]. In contrast, the same P. falciparum genotype 
was found in the women presenting two episodes. The 
second episode occurred 27 days after the first one and 
was a severe case, but the parasite had wild-type allele of 
the K13 gene associated with artemisinin-based combi-
nation therapy resistance [45], suggesting a late therapeu-
tic failure to artemether plus lumefantrine in this woman. 
In Indonesia, dihydroartemisinin-piperaquine is the first 
line of treatment for both P. falciparum and P. vivax in 
pregnant women [46]; therefore, an alternative option 
could be evaluated and considered in Colombia in case 
of artemether plus lumefantrine failure. Finally, as a con-
sequence of the high prevalence of severe MiP cases, this 
study suggests the need for a more careful medical follow 
up during pregnancy in malaria endemic settings.
Conclusions
Prompt diagnosis, effective treatment, and partial acqui-
sition of clinical immunity appear to be associated with 
the high prevalence of uncomplicated MiP. However, 
anaemia and acute renal failure observed warrant more 
detailed studies because of the potential deleterious 
effects on both mother and fetus. This study reinforces 
the need for a more careful medical follow up during 
pregnancy, including malaria diagnosis as part of ante-
natal care for all pregnant women residing in endemic 
areas, to decrease the risk of complications and to avoid 
multiple malaria episodes associated with greater malaria 
severity.
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